Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Complement activity in leukemic patients]

H Thränhardt, J Milleck, F Zintl

    Folia Haematologica (Leipzig, Germany : 1928)
    |January 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Prognostic-significance of protein-kinase-C in newly-diagnosed childhood acute lymphoblastic-leukemia.

    International journal of oncology·2011
    Same author

    Detection of fos, jun and ras in newly-diagnosed childhood acute lymphoblastic-leukemia by immunocytochemistry and PCR.

    International journal of oncology·2011
    Same author

    Resistance factors and proliferative activity in childhood acute nonlymphoblastic leukemia.

    International journal of oncology·2011
    Same author

    Resistance-related proteins in initial and relapsed childhood acute lymphoblastic leukemia.

    International journal of oncology·2011
    Same author

    Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.

    Leukemia·2009
    Same author

    Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I.

    Klinische Padiatrie·2009
    Same journal

    [Recommendations for a medical-meteorologic prognosis for hemophilia].

    Folia haematologica (Leipzig, Germany : 1928)·1990
    Same journal

    [Malondialdehyde formation by platelets of hemophiliacs].

    Folia haematologica (Leipzig, Germany : 1928)·1990
    Same journal

    Genomic carrier detection and prenatal diagnosis of haemophilia A in families at risk using the polymerase chain reaction (PCR).

    Folia haematologica (Leipzig, Germany : 1928)·1990
    Same journal

    Diagnosis of carriers of haemophilia A by RFLP analysis: Austrian results.

    Folia haematologica (Leipzig, Germany : 1928)·1990
    Same journal

    Genomic diagnosis of haemophilia A and B in the German Democratic Republic.

    Folia haematologica (Leipzig, Germany : 1928)·1990
    Same journal

    [Paradoxical bleeding as a complication of the treatment of hemophilia with factor VIII and factor IX preparations].

    Folia haematologica (Leipzig, Germany : 1928)·1990
    See all related articles

    Heterologous anti-leukaemic sera can lyse human leukaemic cells. This cell lysis occurs in both leukaemic and remission phases when specific antibodies are present.

    Area of Science:

    • Immunology
    • Oncology

    Context:

    • Investigating the efficacy of heterologous anti-leukaemic sera in vitro.
    • Evaluating the reactivity of sera from leukaemic patients against leukaemic cells.

    Purpose:

    • To determine if heterologous anti-leukaemic sera can induce lysis of human leukaemic cells.
    • To assess the effectiveness of these sera during different phases of leukemia.

    Summary:

    • In vitro testing demonstrated that heterologous anti-leukaemic sera can cause lysis of human leukaemic cells.
    • This cytotoxic effect was observed in both the active leukaemic phase and during remission.
    • The presence of specific heterologous antibodies was crucial for inducing cell lysis.

    Impact:

    • Suggests a potential therapeutic avenue for leukemia treatment using antibody-mediated cell lysis.

    Related Experiment Videos

  • Highlights the role of specific antibodies in targeting leukaemic cells.
  • Provides insights into the immunological aspects of leukemia and its treatment.